Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protection.
Cell Rep
; 38(5): 110318, 2022 02 01.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1654152
ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines may target epitopes that reduce durability or increase the potential for escape from vaccine-induced immunity. Using synthetic vaccinology, we have developed rationally immune-focused SARS-CoV-2 Spike-based vaccines. Glycans can be employed to alter antibody responses to infection and vaccines. Utilizing computational modeling and in vitro screening, we have incorporated glycans into the receptor-binding domain (RBD) and assessed antigenic profiles. We demonstrate that glycan-coated RBD immunogens elicit stronger neutralizing antibodies and have engineered seven multivalent configurations. Advanced DNA delivery of engineered nanoparticle vaccines rapidly elicits potent neutralizing antibodies in guinea pigs, hamsters, and multiple mouse models, including human ACE2 and human antibody repertoire transgenics. RBD nanoparticles induce high levels of cross-neutralizing antibodies against variants of concern with durable titers beyond 6 months. Single, low-dose immunization protects against a lethal SARS-CoV-2 challenge. Single-dose coronavirus vaccines via DNA-launched nanoparticles provide a platform for rapid clinical translation of potent and durable coronavirus vaccines.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Nanopartículas
/
Vacunas contra la COVID-19
/
SARS-CoV-2
/
COVID-19
Tipo de estudio:
Estudio pronóstico
/
Ensayo controlado aleatorizado
Tópicos:
Vacunas
/
Variantes
Límite:
Animales
Idioma:
Inglés
Revista:
Cell Rep
Año:
2022
Tipo del documento:
Artículo
País de afiliación:
J.celrep.2022.110318
Similares
MEDLINE
...
LILACS
LIS